復星醫藥(02196.HK)子公司創新藥臨床試驗獲批准
復星醫藥(02196.HK)公布,控股子公司復星萬邦收到國家藥品監督管理局同意,丁二酸復瑞替尼膠囊用於間變性淋巴瘤激(酉每)陽性或者c-ros肉瘤致癌因子-受體酪氨酸激(酉每)陽性的IB期至ⅢA期非小細胞肺癌患者腫瘤根治性切除術後的輔助治療開展臨床試驗的批准。
該新藥為創新型小分子化學藥物,擬主要用於治療非小細胞肺癌、非小細胞肺癌等,由公司控股子公司重慶復創醫藥與中國科學院上海藥物研究所共同進行臨床前研究,並獨家許可復星萬邦於中國境內進行獨家開發和商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.